Just looking at the one segment of expenses incurred by this company over the last 3 years
Research and development costs, materials and consultants, Directors’ fees, salaries, superannuation and consulting costs.
Total $5,732,040
Below is the revenue we have been presented with as shareholders for nearly $6,000,000 being spent on the above over the last 3 years
The company loss over that period $18,929,141
A share price of .001c and 2,077,888,336 shares now issued and $1.29m in cash left.
........and the "story" just continues.
Some say that is just business,
I suggest there is a culture attached to this "company" that needs serious attention.
- Forums
- ASX - By Stock
- Ann: Appendix 4C
Just looking at the one segment of expenses incurred by this...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FGL (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.4¢ |
Change
-0.003(6.38%) |
Mkt cap ! $4.293M |
Open | High | Low | Value | Volume |
4.6¢ | 4.6¢ | 4.0¢ | $22.11K | 530.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 8600 | 4.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.8¢ | 21544 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8600 | 0.041 |
1 | 25000 | 0.038 |
1 | 50000 | 0.036 |
1 | 100000 | 0.034 |
1 | 93781 | 0.031 |
Price($) | Vol. | No. |
---|---|---|
0.048 | 21544 | 1 |
0.105 | 72904 | 1 |
0.110 | 52515 | 1 |
0.115 | 5914 | 1 |
0.120 | 200271 | 2 |
Last trade - 14.40pm 15/07/2024 (20 minute delay) ? |
Featured News
FGL (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online